

Outlines of Registered VCs

4BIO Partners LLP



Website

Contact info"AT"4biocapital.com

Website https://www.4biocapital.com

4BIO Capital is a global specialist biotech venture firm investing in breakthrough technologies that solve critical healthcare challenges. 4BIO partners with visionary biotech founders, investing with conviction and serving as a therapeutic navigator to guide the transformation of scientific innovation into life-changing therapies. The 4BIO team are specialists with deep scientific expertise and proven commercial track records, strategically matched to portfolio companies that align with their specific areas of knowledge. For more information, connect with us on [LinkedIn](#) and X [@4biocapital](#) and visit www.4biocapital.com.



Person in charge



Philippe
Fauchet



Kieran
Mudry



Dima
Kuzmin



Tetsu
MARUYAMA

Angel Bridge Inc.



Website

Contact https://angelbridge.jp/contact-en/

Website https://angelbridge.jp/en/

Angel Bridge is an independent venture capital firm that invests in startups across a broad range of sectors, including university and research institution spinouts and deep-tech companies, beginning at the seed and early stages. We are particularly active in drug discovery and other deep-tech fields, where we believe early funding and hands-on support can significantly accelerate the growth of innovative startups. We invest across therapeutic areas and modalities, backing companies that advance science and bring new hope to patients worldwide. Following investment, we provide hands-on support throughout the journey from research to exit. This includes intellectual property strategy, business planning, capital strategy, clinical development planning, regulatory affairs, partnerships with pharmaceutical companies, CROs and CDMOs, global fundraising, recruitment of management talent, KPI development, and corporate governance. Combining expertise in drug discovery and business management, our team strives to be a trusted partner to entrepreneurs bringing innovative medicines originating in Japan to patients around the world.



Person in charge



KASAI
Yutaro



IHARA
Hikaru



KONO
Arisa



SEITA
Takeshi



KAWAMURA
Hitoshi

ANRI Inc.



Website

Contact https://anri.vc/en/contact

Website https://anri.vc/en


ANRI Inc. is a Tokyo-based venture capital firm with extensive experience in seed and early-stage investments, providing support from the inception of business establishment. ANRI is dedicated to fostering technology-driven startups with the potential for global impact, including early-stage investments in biotech ventures focused on innovative drug development. Our team provides comprehensive support in areas such as team building, business strategy, and intellectual property, leveraging both ANRI's internal expertise and a vast network of specialized professionals. Through this AMED grant project, we aim to accelerate R&D and clinical development, transforming cutting-edge technologies from Japan's academic and research communities into groundbreaking therapeutic solutions



Person in charge



MIYAZAKI
Yusuke



SAKAKIBARA
Kazuhiro



KINOSHITA
Miki

* Replace "AT" with "@".

Outlines of Registered VCs

ANV Management, LLC



Website

Contact info"AT"an.vc

Website https://an.vc/

AN Venture Partners (ANV) is a Tokyo- and San Francisco-based venture capital firm that invests in the life sciences sector. ANV was founded by experienced Japanese and US venture capital and finance professionals and has an alliance with ARCH Venture Partners in the US. While Japan generates a large amount of innovative scientific research, its ecosystem faces challenges in creating global companies based on these innovations. ANV connects Japan with the world to help realize Japan’s scientific potential. ANV invests in promising research from Japanese universities or Japanese pharmaceutical companies and supports commercialization by creating companies in the US, including at the pre-startup and early stages. The US offers a more mature ecosystem, a deeper talent pool and a much larger capital market, helping bring these innovations to society more efficiently. ANV ultimately aims for exits through initial public offerings (IPOs), for example on NASDAQ, or sales to global pharmaceutical companies.



Person in charge



Takashi Futami



Ken Horne



Ari Nowacek



Jun Hashimoto

Astellas Venture Management LLC



Website

Contact tadayoshi.hirata"AT"astellas.com

Website https://www.astellasventure.com/

AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients. We make investments in privately owned early-stage biotechnology companies focused on therapeutics programs and platform technologies for discovery and development. After making investments, we provide "Pharma View," based on our long history and experience in the pharmaceutical industry. We also offer business support leveraging the expertise, experience, and global network of our team members to implement portfolio companies' innovations and delivery them to patients more swiftly.



Person in charge



Tadayoshi Hirata



Satoshi Konagai



Shinichi Miyake

B Capital Group Management, L.P



Website

Contact ir"AT"b.capital

Website https://b.capital/

Led by Eduardo Saverin, Raj Ganguly and Howard Morgan, B Capital is an investment firm built to support early to late-stage innovators carving new paths in Technology, Healthcare, Energy & Resilience and beyond. As the world races to evolve how we live and work, B Capital supports bold entrepreneurs using technology in extraordinary ways. Through in-house platform team and strategic partnership with Boston Consulting Group, B Capital goes beyond to provide founders with the knowledge, tools and connections they need to scale across borders and boundaries.



Person in charge



Robert Mittendorf
MD



Kelly Qiao
PhD

* Replace "AT" with "@".

Outlines of Registered VCs

Beyond Next Ventures Inc.



Website



Person in charge



SAWABE Takehiko



YATO Keigo

Contact <https://beyondnextventures.com/contact/>

Website <https://beyondnextventures.com>

Since our founding, we have supported the growth of deep tech startups through investment and commercialization support. We have managed funds totaling JPY 48 billion and provide the capital, talent, expertise, and networks needed to commercialize research through company creation from the pre-incorporation stage, executive talent matching, and the TECHNIUM Global Conference. Under AMED’s V-eco program, two of our portfolio companies have been selected as of September 2026, with Beyond Next Ventures serving as the certified lead VC for both. We support companies develop concrete business and R&D plans from the earliest stages. Our investment professionals and expert advisors in biotech support R&D strategy, business development, and management team formation, while our network of CROs, CDMOs, and other external partners provides access to relevant expertise and potential collaborators. Through these integrated capabilities, we support biotech in advancing their R&D, business development, and organizational development, contributing to the enhancement of their business value.

Blackstone Life Sciences (BXLS)



Website



Person in charge



Ari Brettman



Peter Renehan

Contact [pressinquiries"AT"blackstone.com](mailto:pressinquiries)

Website <https://www.blackstone.com/our-businesses/life-sciences/>

Blackstone is the world’s largest alternative asset manager. We seek to deliver compelling returns for institutional and individual investors by strengthening the companies and assets in which we invest. Blackstone Life Sciences focuses on funding clinical development of innovative medicines and medical technologies. Our goal is to bring vital medicines and technologies to market by designing, funding and executing clinical trials for products. Blackstone Life Sciences combines its clinical, commercial and operational expertise with Blackstone’s global network, access to capital, and infrastructure. We commit our skill and scale to select, fund and advance what we believe to be the most promising life science products and companies through hands-on involvement and directly applied expertise.

Catalys Pacific, LLC



Website



Person in charge



TAKESHI Takahashi

Contact [info"AT"catalyspacific.com](mailto:info)

Website <https://catalyspacific.com/>

Catalys Pacific is an independent venture capital firm focusing on early-stage investments in life sciences. The firm’s mission is improving patient lives worldwide by driving impact and innovation in healthcare and contributing to advancements in life sciences. Founded in 2019, the firm acts as a trusted regional partner, building companies and catalyzing transpacific partnerships to fulfill its mission. The Catalys Pacific team is based in Tokyo, Japan and Seattle, Washington. Learn more at website.

* Replace “AT” with “@”.

Outlines of Registered VCs

Cure Ventures



Website

Contact info"AT"curevc.com

Website https://www.curevc.com/

Founded in 2021, Cure Ventures is a Boston-based life sciences venture capital firm focused on creating and investing in biotechnology companies grounded in human genetics and strong biological rationale. We target early-stage therapeutic programs across multiple disease areas and modalities.

Alongside seed capital, our experienced team provides hands-on leadership in management and R&D, supporting founders from company formation through clinical proof of concept. Our proprietary human genetics platform, Mendel, informs target assessment, biomarker selection, and clinical development strategy.

Through collaboration with Japanese researchers, entrepreneurs, investors, and pharmaceutical companies, we aim to translate Japan-originated science and therapeutic assets into globally competitive companies. We provide scientific and operational support alongside access to international investors and pharmaceutical partners.



CURE VENTURES

Person in charge



David Fallace, JD, MBA
Managing Partner



Richard Lim, MBA
Managing Partner



Louis Tartaglia, PhD
Managing Partner



Lyle King, PhD
Senior Associate

Curie.Bio



Website

Contact https://curie.bio/contact-us/

Website https://curie.bio/

Curie.Bio combines investment capital with an integrated team of drug makers, development experts, and operators to help founders translate therapeutic ideas into medicines. We invest across therapeutic areas, modalities, and geographies, from concept through clinical proof of concept.

Our 100+ person team works as an extension of each portfolio company, helping define the target product profile, design and execute both the discovery and the development plan, manage external partners, and build the evidence needed for the next value inflection point.

We have raised \$1.25B across two funds. The Seed Fund advances programs through key preclinical milestones, including development candidate selection. The Breakout Fund supports clinical development through meaningful human activity data.

Curie.Bio

Person in charge



Ben Auspitz
Breakout Fund,
Managing Partner



Ricardo
Dolmetsch, PhD
Seed Fund, Partner



Lisa Huang,
PhD
Drug Maker, CxO

D3LLC



Website

Contact info"AT"d3growth.com

Website https://www.d3growth.com/

D3 LLC is a Tokyo-based biotech and healthcare venture capital firm dedicated to improving global health from Japan. We believe the country's outstanding science can give rise to companies that compete on the world stage, and we back and build them to global standards. Our team pairs M.D., Ph.D., and R.Ph. training with experience at McKinsey, Novartis, and an international VC firm, as well as in founding a startup. We invest in early-stage therapeutics, digital health and beyond, regardless of modality or approach. We keep a deliberately concentrated portfolio so our partners can work hands-on with every company, from Discovery through Development and Deployment. We already back companies leading their fields worldwide and others foundational to healthcare in Japan and Asia. We welcome international investors seeking a trusted co-investor and on-the-ground partner in Japan.



D3 LLC

Discovery Development Deployment

Person in charge



Tomoya
Nagata



Kenji
Watatani



Yasuaki
Hasebe

* Replace "AT" with "@".

Outlines of Registered VCs

DBJ Capital Co., Ltd.



Website



Contact <https://www.dbj-cap.jp/contact/>

Website <https://www.dbj-cap.jp/en/>

DBJ Capital invests in wide range of industries as the venture capital arm of the Development Bank of Japan (DBJ). Life science sector is one of the focus areas of DBJ Capital. We have venture capitalists with extensive business and investment experience in this field and invest approximately 30% of our fund in this sector. As for hands-on activities, we focus on supporting fundraising, business management, recruitment, R&D, and business development, etc. We are unique in supporting alliances with large companies and domestic and international life science VCs by leveraging DBJ's client base. For more information, please visit our website.

Person in charge



Hisashi Mitsuguchi



Yorinobu Yasuda



Takeshi Shimada

DCI Partners Co., Ltd.



Website

DCI Partners

Contact [dcip_info"AT"daiwa.co.jp](mailto:dcip_info)

Website <https://www.daiwa-inv.co.jp/dcip/en/>

We have over 20 years' history of investing in biotech start-ups. We are currently managing the largest size of the life science fund in Japan and playing a key role in supplying funds to promising start-ups. We aim at increasing the value of our portfolios by providing various hands-on supports utilizing our team's expertise of clinical development, intellectual property and business development as well as our extensive network across academics, biotech and pharmaceutical industry primarily in Japan and Taiwan. Beyond classical venture capital firms, we act as a platform to incubate seeds and create new start-ups that have great potential.

Person in charge



Junichi Yokota



Shoma Tanaka



Yuka Niimi

Deerfield Management



Website

DEERFIELD[®]
Advancing Healthcare[®]

Contact [contact"AT"deerfield.com](mailto:contact)

Website <https://deerfield.com>

Deerfield is an investment management firm committed to advancing healthcare through investment, intelligence, and philanthropy. The Deerfield ecosystem is headquartered at Cure[®], a premier healthcare innovation campus in New York City, and includes Deerfield Discovery and Development (3DC), the firm's internal research & development engine, and Deerfield Intelligence, the firm's data, technology, and artificial intelligence arm. Deerfield works across the healthcare ecosystem to connect people, capital, ideas, and technology in bold, collaborative, and inclusive ways.

Person in charge



Dave Greenwald



Michael Hurley



Brian Chow



Andrew ElBardissi



Jason Fuller



Howie Furst



Jonathan Leff



Joseph Pearlberg



Cameron Wheeler

* Replace "AT" with "@".

Outlines of Registered VCs

Eight Roads Ventures Japan (Eight Roads Capital Advisors Hong Kong Limited) Contact admin"AT"eightroads.com Website https://eightroads.com/en/		 Website	8[∞] EIGHT ROADS™ Person in charge  KOMOTO Shinichiro
EQT Life Sciences Contact dealflow"AT"eqtpartners.com Website https://eqtgroup.com/private-capital/eqt-life-sciences		 Website	 Person in charge  Fouad Azzam  Vincent Brichard  Laurenz Govaerts
Fast Track Initiative, Inc. Contact v-eco-inquiry"AT"fti.vc Website https://fti.vc/		 Website	 Person in charge  KIMURA Hiroko  YASUDA Koji  KIRIYA Keita

* Replace "AT" with "@".

Outlines of Registered VCs

F-Prime Capital Partners
(Impresa Management LLC)



Website

Contact admin"AT"eightroads.com

Website https://fprimecapital.com/

Global venture capital firm with 20+ years experience in providing biotech startup with patient capital and hands-on support, based in US and cross-boarder to Japan, China, India and Europe. Deep analysis and understanding to science and technologies that can solve unmet medical needs and social problem. Stage agnostic investment from pre-foundation stage or seed stage, to later growth stage. Japan is one of focusing areas by co-working with the sister fund, Eight Roads Ventures Japan.

F-PRIME

Person in charge



Shinichiro
Komoto



Robert
Weisscoff



Brian
Yordy

JAFCO Co., Ltd.



Website

Contact https://jafco.co.jp/english/contact/

Website https://jafco.co.jp/english/

We understand and deeply empathize with the aspirations of entrepreneurs to realize their businesses. We have executed investments of several hundred million yen, mainly in the seed/early stage, and have continued to execute investments after the initial round. The investment theme of the Investment Group for Academy & Life Science is to capture and dedicate the technological innovations that will change the world. The main areas of our investment are biotech, medical device, and health technology, which are essential to society, have high growth potential, and are expected to expand their markets, and we support the challenges of companies that aspire to innovative and creative management. We have been actively supporting biotech since the dawn of investment in Japan and have accumulated a great deal of knowledge and network. We concentrate our investments on next-generation innovative technologies and medical seeds that can be delivered to a large number of patients.

JAFCO

Person in charge



KITAZAWA
Tomotake



KOBAYASHI
Taira



ISHIMOTO
Yuki



UENO
Suguru

JIC Venture Growth Investments Co., Ltd.



Website

Contact info_lifescience"AT"j-vgi.co.jp

Website https://www.j-vgi.co.jp/en/

JIC Venture Growth Investments Co., Ltd. (JIC VGI), the venture capital arm of the Japan Investment Corporation (JIC) Group, strategically supports innovation in Japan and enhances the global competitiveness of Japanese industries. Focused on investments across the life sciences sector from early to late stages, JIC VGI helps startups grow through its extensive global network of venture capital firms, pharmaceutical companies, and government agencies. Through these efforts, we contribute to strengthening Japan's venture ecosystem and advancing the development of innovative medicines originating in Japan.



Person in charge



URUNO
Yoshiharu



SUZUKI
Hanae



TSUZUKU
Takuma



GOTO
Takahiro

* Replace "AT" with "@".

Outlines of Registered VCs

Keio Innovation Initiative, Inc.		 Website	 Person in charge  Tomokatsu Hongo
Contact hongo"AT"keio-innovation.co.jp Website https://www.keio-innovation.co.jp/en/		Keio Innovation Initiative, Inc. (KII) is dedicated to its mission: "Let us help your research, your invention, your innovation change the world." We invest in the deep tech start-ups originating from Japanese leading universities and research institutions other than Keio University and, providing hands-on support to drive forward the incorporation of excellent results into society. For this program specifically, we invest in start-ups at various stages, from drug discovery to clinical trials, and support the advancement of both clinical and business development.	
Kyoto University Innovation Capital Co., Ltd.		 Website	 Person in charge  Hiroyuki Ueno  Osami Kono  Tsuyoshi Tsujimura Kazunori Yoshikawa Tohru Ozawa
Contact https://www.kyoto-unicap.co.jp/contact/ Website https://www.kyoto-unicap.co.jp/		Kyoto University Innovation Capital Co., Ltd. (Kyoto iCAP) is a venture capital firm wholly owned by Kyoto University, a national university corporation. We invest in startups that use research from Kyoto University and other national universities to create new industries. Our support spans team building, business planning, company formation, investment, and growth. In March 2026, we established our third fund (Innovation Kyoto 2026 Investment Limited Partnership), with a target size of JPY 20 billion. In drug discovery, we help biotech startups turn innovative university research into medicines for patients. Our support includes developing research and development plans and fundraising strategies, and connecting companies with pharmaceutical partners and investors in Japan and abroad. As a certified venture capital firm under AMED's Drug Discovery Venture Ecosystem Enhancement Program, we invest in and support biotech startups developing new treatments and vaccines.	
Mission BioCapital		 Website	 Person in charge  Johannes Fruehauf  Doug Crawford  Steve Tregay  Peter Parker

* Replace "AT" with "@".

Outlines of Registered VCs

Mitsubishi UFJ Capital Co., Ltd.



Website

Contact ninteivc"AT"mucap.co.jp

Website https://www.mucap.co.jp/english/

Mitsubishi UFJ Capital is the venture capital arm of Mitsubishi UFJ Financial Group. Since 2017, we have established life science funds totaling ¥50 billion, including the Mitsubishi UFJ Life Science Fund IV (¥20 billion). We aim to help build a strong drug discovery ecosystem in Japan through investments in university spin-offs, pharmaceutical carve-outs, and open innovation projects between academia and pharmaceutical companies. Our team includes professionals with pharmaceutical industry experience, and we work closely with specialized partners in intellectual property, non-clinical studies, manufacturing, and clinical development to support start-ups from the pre-investment stage onward.



Mitsubishi UFJ Capital

Person in charge



HASEGAWA
Hiroyuki



SHINOZAKI
Mikihiro



KAKIUCHI
Akihito



TANAKA
Hiroaki

MORI
Daisuke

IZAWA
Yosuke

KUBO
Yuki

KATO
Ryo

MIYAKO Capital Co., Ltd.



Website

Contact info"AT"miyakocapital.com

Website https://miyakocapital.com/en

We will invest in technology development-focused startup companies that utilize advanced intellectual assets from academia and research institutions, such as Kyoto University, across all stages, from seed and early stages (our main focus) to middle and later stages, contributing to the SDGs. Additionally, we aim to foster the creation of next-generation leading industries and innovations through growth support activities such as industry-academia collaboration leading to the social implementation of technology. We will continuously support each company by implementing effective industry-academia collaboration strategies tailored to its circumstances and needs. Furthermore, since all our members have extensive experience in VC investments in Japan and overseas, including the United States, as well as in managing startup companies, we will also provide thorough hands-on support in practical aspects as a complement. In this program, especially regarding drug discovery startups, we intend to actively support the challenges of those who come from pharmaceutical companies and contribute to updating the drug discovery startup ecosystem.

MIYAKO
CAPITAL

Person in charge



MISAWA
Hiroyuki



OTANI
Takayuki



TAMIYA
Taiga

Newton Biocapital Partners



Website

Contact https://newtonbiocapital.com/ja/contact

Website https://newtonbiocapital.com/en/about

Our Mission: Value creation for all by leveraging innovation to develop solutions for chronic health conditions, we help create value for:

Patients, by funding efforts for affordable healthcare solutions matching unmet medical needs

Society, by easing pressure on insurance/reimbursement systems burdened by chronic health conditions

Local ecosystems, by attracting investors and promoting company growth which leads to improved sector employment

Investors, by supporting portfolio company value creation, and setting the scene for successful exits



NEWTON
BIOCAPITAL

Person in charge



アライ タカヒロ
チーフ・ストラテジック
オフィサー
ICED



加藤 隆志
取締役
ICED



加藤 隆志
チーフ・ストラテジック
オフィサー
ICED



加藤 隆志
チーフ・ストラテジック
オフィサー
ICED

* Replace "AT" with "@".

Outlines of Registered VCs

OSAKA University Venture Capital Co., Ltd.		 Website	 Person in charge  UOTANI Akira  TAGA Yuki  ASANO Shigehiro  UEHIRA Masahiro  SATO Hiroki  SHIMEKAKE Yoshiyuki
ContactInfo"AT"ouvc.co.jp Websitehttps://www.ouvc.co.jp/en/ Osaka University Venture Capital Co., Ltd. (OUVC) is a venture capital firm that supports ventures utilizing outstanding research outcomes not only from Osaka University but also from other national universities. ① Up until now, we have track records of investing primarily in the medical and pharmaceutical fields, and we have provided comprehensive support from startup to exit assistance. ② In recent times, we are focusing on finding CxO talent. We also leverage our status as a venture capital funded 100% by Osaka University and place emphasis on specialized hands-on support, including regulatory authority interactions, in collaboration with Medical Center for Translational Research Osaka University Hospital. We are ready to accept consultations from researchers at national universities who are not yet fully prepared for entrepreneurship, particularly focusing on national university settings. For more detailed information and contact details, please refer to our website.		 Website	 Person in charge  Laura Tadvalkar, PhD  Josh Resnick, MD
Contactrequest"AT"racap.com Websitehttps://www.racap.com/ RA Capital Management, L.P. is a U.S.-based healthcare and life sciences investment manager. Since 2004, it has funded and built companies from formation and seed financing through venture, crossover, IPO, and public-market stages. RA Capital combines scientific diligence with flexible, multi-stage capital. Dedicated teams and proprietary platforms support therapeutic landscape analysis, clinical and regulatory strategy, company formation, team and board building, business development, and financing. Investment professionals often serve as directors or observers for private portfolio companies. Through the AMED program, RA Capital seeks to partner with Japanese pharmaceutical startups advancing differentiated therapeutics and platforms from preclinical development through early clinical proof of concept. RA Capital aims to support global development plans and access to international capital and strategic partners, helping advance medicines for patients worldwide.		 Website	 Person in charge  Taro Inaba  Taka Koda  Kazu Nonomura  Kyoko Matsumoto

* Replace "AT" with "@".

Outlines of Registered VCs

Saisei Ventures LLC



Website

Contact info"AT"saiseiventures.com

Website https://www.saiseiventures.com/

Saisei Ventures is a life science venture capital firm dedicated to building next generation companies in the healthcare sector. We create ventures that start from bold ideas and empower dynamic entrepreneurs by providing technical, operational, and financial guidance. Our approach combines Western expertise and Japanese innovations to build globally competitive companies that will have the greatest impact on patient lives. With operations in Japan and the United States, Saisei aims to enhance the value of its portfolio by leveraging its unique networks and the institutional advantages of both countries. For more information, please visit <https://www.saiseiventures.com/>.



Person in charge



SAITO
Hikaru



Jonathan
Yeh



Sven Kili

SV Health Investors



Website

Contact info"AT"svhealthinvestors.com

Website https://svhealthinvestors.com/

SV Health Investors is a global life sciences venture capital firm with operations in London, UK and Boston, USA, focused on building and supporting innovative biotechnology companies. We invest across stages, from company creation and early translational research to clinical development, working closely with academic and industry partners to advance high-quality science into viable medicines.

SV Health Investors manages the Dementia Discovery Fund (DDF), which invests in therapeutics companies targeting dementia and neurodegenerative diseases, as well as multiple biotech funds investing in therapeutically-focused companies addressing significant unmet medical needs. With deep scientific and operational expertise, the team takes an active, hands-on approach to company building while emphasizing clear communication, appropriate governance, and long-term value creation for patients worldwide.

We look forward to serving as a strong and trusted partner, particularly for biotechnology companies aiming to expand globally.



Person in charge



Miles
Gerson



Laurence
Barker



Nikola
Trbovic



Jamil Beg

Taiho Innovations Ltd.



Website

Contact https://www.taihoinnovations.com/contact/

Website https://www.taihoinnovations.com/

Taiho Innovations is the corporate venture capital arm of Taiho Pharmaceutical, a Japanese specialty pharmaceutical company focused on oncology and immunology related diseases. We invest in early-stage Japanese biotech startups with promising seeds and platform technologies for drug discovery. In addition, Taiho Innovations is actively engaged in incubation programs for academia, supporting researchers in testing and growing their game-changing ideas as well as launching new startup companies. Our team has extensive experience in both international investment and pharmaceutical R&D, enabling us to provide not only financial backing but also comprehensive, hands on support to improve human health globally.



Person in charge



SHIMOMURA
Toshiyasu



MORI
Fumitaka



MIYAKOSHI
Hitoshi



MAEDA
Masatoshi

* Replace "AT" with "@".

Outlines of Registered VCs

Taiho Ventures, LLC



Website

Contact info"AT"taihoventures.com

Website https://taihoventures.com/

Taiho Ventures, LLC is a strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharma focusing on oncology and immune-related diseases. We actively invest in early-stage private companies in the areas of our focus and review a wide variety of modalities including biologics and small molecules. Taiho Ventures focuses on delivering cutting-edge technologies and therapies of startups to society not only by providing financial support but also by leveraging its experience in research and development and business management. The company also considers option type of investments and spin outs, in addition to the pure equity investments



Person in charge



Sakae Asanuma



Takaaki Ishii

The Column Group LLC



Website

Contact David Liu
dliu"AT"thecolumngroup.com

Website https://thecolumngroup.com

The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early-stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics. TCG takes a novel approach to venture capital funding with an edge-to-edge investment model primarily focused on company formation but with the financial wherewithal for long-term private and public capital support.

TCG emphasizes focus, we believe that the most critical resources - such as great ideas, world class founders, and top quality managerial and scientific talent - are very rare and that concentrating them within a small cohort of companies is the key path to success.

TCG is about the bold pursuit of big ideas using innovative science to generate breakthrough therapies that address significant diseases. Our firm is committed to all facets of company building and brings together a rich combination of scientific, financial and operational expertise to shape promising science into a value-rich portfolio poised to have a profound impact on human health.



Person in charge



Peter
Svennilson



Tim
Kutzkey



Leon Chen



Jeff Goater

The University of Tokyo Edge Capital Partners Co., Ltd. (UTEC)



Website

Contact ls-kanri"AT"ut-ec.co.jp

Website https://www.ut-ec.co.jp/english/

Since its inception in April 2004, UTEC, in collaboration with entrepreneurs and researchers, has been investing in numerous startups that are tackling global challenges and advancing human progress. In the field of drug discovery, UTEC's investments span a diverse range of startups focusing on assets such as peptides, nucleic acids, cellular genes, and small molecules, as well as those equipped with advanced drug discovery platform technologies. These efforts are directed towards addressing areas of disease where new treatments are eagerly anticipated. Our members of highly specialized professionals in life sciences and drug discovery leverage our expertise and networks across various domains, including research and development, clinical trials, regulatory affairs, business development, and management and administration. We contribute significantly to the business expansion of drug discovery startups, both within Japan and internationally.



Person in charge



USAMI
Atsushi



SHIOHARA
Azusa



IMAHASHI
Kenichi

* Replace "AT" with "@".

Outlines of Registered VCs

TPG Life Sciences Innovations (TPG LSI)		 Website	 Person in charge  Shinichiro Fuse, PhD  Lucian Iancovici, MD  Carolyn Ng, PhD
Contact TPGLSIinfo"AT"tpg.com Website https://www.tpg.com/platforms/growth/tpg-life-sciences-innovation		TPG Life Sciences Innovations (TPG LSI) is a dedicated life sciences investment platform focused primarily on investing in innovative therapeutics companies and providing inflection capital to support the path to clinical proof-of-concept. The strategy combines deep scientific and clinical expertise with the resources, network, and healthcare experience of TPG’s global investment platform.	
UTokyo Innovation Platform Co., Ltd.		 Website	 Person in charge  Makoto (Mark) Ohori, Ph.D.  Atsuhiro (Atsu) Bingo, Ph.D.
Contact https://www.utokyo-ipc.co.jp/en/contact/ Website https://www.utokyo-ipc.co.jp/en/		UTokyo Innovation Platform Co., Ltd. (UTokyo-IPC) is a wholly-owned investment company by the University of Tokyo, actively investing in venture projects that utilize the achievements of the University of Tokyo and other universities. We provide hands-on support from experienced capitalists with a rich history of pharmaceutical investments, business development, and exit strategies in the United States and Japan. We welcome contact with bio-tech ventures engaged in innovative technology development, ranging from preclinical to Phase 2 clinical trials.	

* Replace “AT” with “@”.